HTG Molecular Diagnostics, Inc. announced it has appointed Robert Spitale, Ph.D., Associate Director and Associate Dean of Research in the School of Pharmacy and Pharmaceutical Services at the University of California, Irvine (UC Irvine), to the HTG Therapeutics Scientific Advisory Board. Dr. Spitale is a chemical biologist with extensive training in genomics and cell biology, and is internationally recognized as a leader in the field of RNA structure and function. His research has focused on developing novel chemical and bioinformatic approaches to better understand how RNA molecules orchestrate gene expression pathways and contribute to disease pathology.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0025 USD | 0.00% | 0.00% | +92.31% |
2023 | Motion for De Minimus Asset Sale Approved for HTG Molecular Diagnostics, Inc. | CI |
2023 | Motion for De Minimus Asset Sale Filed by HTG Molecular Diagnostics, Inc. | CI |
1st Jan change | Capi. | |
---|---|---|
+92.31% | 5.54K | |
-42.18% | 2.85B | |
+22.02% | 1.94B | |
+0.39% | 1.68B | |
+27.15% | 1.26B | |
-10.70% | 1.03B | |
-18.27% | 938M | |
+0.66% | 783M | |
-25.07% | 628M | |
+14.62% | 535M |
- Stock Market
- Equities
- HTGMQ Stock
- News HTG Molecular Diagnostics, Inc.
- HTG Molecular Diagnostics, Inc. Appoints Dr. Robert Spitale to Therapeutics Scientific Advisory Board